Thank you!
Your support is sustaining the future of local news in our communities.

Omicron, surely that’s enough

What have the scientific, pharmaceutical, and medical communities done to stifle SARS-CoV-2 infections? There are currently 18 advanced trials of different vaccines, 64 possible new treatments, and 23 potential or approved anti-viral drugs.

The mRNA vaccines from Pfizer and Moderna provide robust protection. (The mRNA technology is being expanded to HIV, malaria, and other diseases for which conventional vaccines have failed.) mRNA vaccines are expensive and need to be shipped frozen. Lower income countries require an effective vaccine that is inexpensive, survives at higher temperature and can be made locally.  Corbevax, created at Baylor College of Medicine, fits these criteria and is currently being made in hundreds of millions of doses in India. Other vaccines (Novovax) produce antibodies to viral proteins in addition to the Spike protein. The Novovax vaccine contains no genetic material.

Beyond vaccines there are 64 new treatments in development that block or slow infection or some of its consequences, like inflammation. Inflammation makes blood vessels leaky; defensive cells, which rush to the site of infection, squeeze out of the circulation, and infiltrate the lungs. They fill air sacs with dead neutrophils, eosinophils, and fluid, making the patient struggle to breathe.  In addition to the inflammatory reaction, when these cells die they release digestive enzymes that can do terrible damage to the lungs or other infected tissues. The use of steroids to inhibit inflammation was a critical early discovery. According to a review I read recently, it is still the best early intervention. Most viruses have means to inhibit a host’s immune system:  some inhibit interferon synthesis, a critical mobilizer of the immune response; SARS-CoV-2 inhibits the production of Natural Killer cells, which recognize infected lung cells and kill them. The more we know about these mechanisms the better off we will be.

There are currently 23 antivirals approved or in testing, including Merck’s Molnupiravir and Pfizer’s Paxlovid, but others have Emergency Use Authorizations as well. Paxlovid, if taken within 5 days of the onset of symptoms, blocks disease progression and keeps 90% of patients from hospitalization.  As a result, our hospitals are able to function, saving money, reducing misery and increasing morale.  Vaccinated and boosted people usually have a short illness unless they have other complications and may not need these therapeutics. But for those who do, or are unvaccinated the drugs are becoming available in pharmacies.

My friend, Jonathan Sanoff, keeps track of these things. He told me about a site called the Therapeutics Locator, which The Assistant Secretary for Preparedness and Response at The Department of Health and Human Services and her staff have prepared. The Assistant Secretary is Rear Admiral Rachel L. Levine, MD. The site tells potential patients where to find these drugs, whether they are in Puerto Rico or Alaska. For skeptics, the site also includes the number of doses on hand at each site and the total made so far, as well as information on each drug. As new therapies come online, they will appear on the Therapeutics Locator. There are currently seven drugs and monoclonal antibodies on the site. The Asst Secretary and her staff do not get much credit, but they should. See: www.covid-19-therapeutics-locator-dhhs.hub.arcgis.com/.

It is important to have many anti-viral drugs, and I was surprised to learn that 23 are still in late clinicals trials. We learned from HIV therapy that an RNA virus can develop resistance to a single drug but cannot evolve resistance to three drugs and is why the number 23 is a pleasant surprise. An even better surprise is, some of these drugs inhibit other RNA viruses, including Zika and Ebola.

Nothing in science or medicine must work, no matter how clever the idea. We should not be surprised that 26 vaccines failed, 92 treatments did not pass muster, and 54 antivirals did not inhibit SARS-CoV-2.  These results on therapies in the development pipeline have been collected by Heidi Ledford, one of Nature Magazine’s senior reporters (Nature, March 3, 2022). I am grateful to her. In that context, the March 11 issue of Science, the flagship publication of the American Academy of Sciences, contains a detailed comparison and analysis of these treatments and ideas on what we need to prepare for the next epidemic. Pandemics are too large a subject to cover everything — we have left out the value of logistics and convincing people to take vaccines, not to mention long Covid, but people are studying these challenges. The combination of basic science, private industry, and public health services have done well, although praise sounds hollow when millions have died.

What to do? Get vaccinated and boosted. When new boosters designed to attack SARS-CoV-2 or its variants appear, get those too. Even with the vaccine, you may get mild disease, but the name of the game is to prevent progress to serious disease and hospitalization. The new drugs offer reassurance. In places where the virus and infection are in decline, it is time to resume normal life.  Or at least that is my plan.

 

Richard Kessin is Emeritus Professor of Pathology and Cell Biology at the Columbia University Irving Medical Center. Reach him at Richard.Kessin@gmail.com. His website contains more information: RichardKessin.com.

 

 

       

             

 

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

Voices from our Salisbury community about the housing we need for a healthy, economically vibrant future

Renee Wilcox

If you’ve ever wandered through Paley’s Farm Market, you probably know Renee Wilcox. For thirty years, she has been greeting you with unmistakable warmth—always ready with a smile. Renee grew up in Millerton, but it was in Salisbury that her family found something they’d never had before: a true sense of home. In 2003, she and her husband Bill were living in Millerton, but Bill—a volunteer with the Lakeville Hose Company—was already part of Salisbury life. When the Salisbury Housing Trust finished eight new homes on East Main Street (Dunham Drive), Renee and Bill were the first to sign on.

The story of those houses is really a story about the best parts of our community. Richard Dunham and his wife, Inge, along with the Housing Trust board, poured years of energy and hope into the project. Renee can’t help but light up when she talks about the people who helped her family settle in. Digby Brown came by to install appliances and bathroom cabinets; Barbara Niles spent hours painting; Carl Williams assembled bunk beds for the kids. Rick Cantele, at Salisbury Bank, helped them with their finances so they could qualify for a mortgage, while neighbors arrived at their door with fruit baskets and welcoming words.

Keep ReadingShow less
Trade Secrets: a glamorous garden event with a deeper mission

Heavy stone garden ornaments, a specialty of Judy Milne Antiques from Kingston, at Trade Secrets 2025.

Christine Bates

Tucked away on Porter Street in downtown Lakeville, Project SAGE is an unassuming building from a street view. But cross the threshold a week before Trade Secrets — one of the region’s biggest gardening events, long associated with Martha Stewart and glamorous plants of all varieties — and you’ll find a bustling world of employees and volunteers getting ready for the organization’s most important event of the year.

“It’s not usually like this,’ laughed Project SAGE director Kristen van Ginhoven. “But with Trade Secrets just around the corner, it’s definitely like this.”

Keep ReadingShow less
Two artists, two Hartford stages, one shared life

Caroline Kinsolving and Gary Capozzielo at home in Salisbury with their dogs, Petruchio and Beatrice

Provided
"He played his violin, I worked on my lines, we walked the dog, and suddenly we were circling each other perfectly."
Caroline Kinsolving

Actor Caroline Kinsolving and violinist Gary Capozziello enjoy their quiet life with their two dogs in Salisbury, yet are often pulled apart to perform on distant stages in far-flung cities. Currently, the planets have aligned, and both are working in Hartford, across Bushnell Park from one another. Bridgewater native Kinsolving is starring in “Circus Fire,” the current production of TheaterWorks Hartford, while Capozziello is a violinist and assistant concertmaster of the Hartford Symphony Orchestra. While Kinsolving hates being away from home, she feels the distance nourishes their relationship.

“We are guardians of each other’s confidence and self-esteem,” she said.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Local filmmaker turns spotlight back on Hollywood’s Mermaid

Esther Williams in “Million Dollar Mermaid” (1952).

Provided

For decades, Esther Williams was one of Hollywood’s brightest stars, but the swimming sensation of the silver screen has largely faded from public memory — a disappearance that intrigued Millerton filmmaker Brian Gersten and inspired him to revisit her legacy.

As a millennial, Gersten grew up largely unaware of Williams’ influential career. His teen years in Chicago were spent with friends who obsessed over movies, spending hours at their local independent video store,and watching anything that caught their eye. Somehow, though, they never ventured into the glossy world of synchronized-swimming musicals of the 1940s and ‘50s.

Keep ReadingShow less
Summer exhibition opens at Wassaic Project

Nate King, “When I Was Younger And Now That I’m Older,” 2026, Digital projection, digital animation, photography.

photo courtesy Nate King

The Wassaic Project, the 8,000-square-foot, seven-story former grain elevator transformed into a vibrant arts space, opens its 2026 Summer Exhibition, “Because, now is the time of monsters,” on Saturday, May 16, from 3-6 p.m. at Maxon Mills, launching a season-long presentation featuring 39 artists working across installation, performance, video and sculpture.

The opening celebration will include an afternoon of exhibitions and live programming throughout the historic mill building and its surrounding spaces. Gallery and Art Nest hours run from 12-6 p.m., with special presentations scheduled throughout the day.

Keep ReadingShow less
Hotchkiss to host inaugural International Piano Competition
Murong Yang ’08, a founding supporter of the Hotchkiss International Music Competition, helped establish the program through the Yang and Hamabata families to support young musicians and artistic excellence.
Provided

The Hotchkiss School will launch a major new addition to its arts programming with the inaugural Hotchkiss International Piano Competition, a three-day event taking place May 15–17 in Katherine M. Elfers Hall.

The competition will bring together young pianists ages 10 to 18 from around the world, with participants representing the United States, Thailand, Korea, China, Canada, and Azerbaijan. Performers will compete across multiple age divisions, culminating in final rounds that will be open to the public, offering audiences the opportunity to hear a wide range of emerging international talent in performance.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.